Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 15Terminated 6Withdrawn 1Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 23Myeloid 17Sarcoma 9Gastrointestinal 7Lymphoid 6Tumor-Agnostic 2Other solid neoplasm 2Dermatologic 2Thoracic 1Head & Neck 1CNS 1

Conditions

Meningioma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 66Radiotherapy 52Carboplatin 25Bevacizumab 21Cisplatin 19Radiosurgery 18Vincristine 17Etoposide 17Cyclophosphamide 17Surgical Procedures, Operative 13Magnetic Resonance Spectroscopy 13Chemotherapy, Adjuvant 11Melphalan 10Lomustine 10Drug Therapy 10Filgrastim 9Erlotinib Hydrochloride 9apatinib 8Pemetrexed 83-Iodobenzylguanidine 8anlotinib 7Radiation 7Peripheral Blood Stem Cell Transplantation 7Methotrexate 7Thiotepa 6Isotretinoin 6Irinotecan 6Ifosfamide 6Doxorubicin 6Carmustine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Imatinib Mesylate × CNS × Clear all
NCT00904735 2013-08-12

Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma

National Cancer Institute (NCI)

Phase 2 Unknown
76 enrolled
CNS

Brain Neoplasms, Meningioma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡